Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3′-kinase/protein kinase B in prostate cancer cells

Clinical Cancer Research

Volumn 9, Issue 7, 2003, Pages 2416-2425

  Mabjeesh, Nicola J ^a   Willard, Margaret T ^a   Frederickson, Carrie E ^a   Zhong, Hua ^a   Simons, Jonathan W ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANTIANDROGEN; ANTIBODY; BICALUTAMIDE; EPIDERMAL GROWTH FACTOR; FLUTAMIDE; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2; LIGAND; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN; PROTEIN KINASE B; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTICLE; AUTOCRINE EFFECT; CANCER CELL; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFECT; DRUG POTENCY; HUMAN; HUMAN CELL; HYPOTHESIS; INCUBATION TIME; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; REGULATORY MECHANISM; REPORTER GENE; RNA TRANSLATION; STIMULATION; TRANSCRIPTION INITIATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANDROGENS; BLOTTING, WESTERN; CELL LINE, TUMOR; CHROMONES; CULTURE MEDIA, CONDITIONED; DIHYDROTESTOSTERONE; DNA-BINDING PROTEINS; ENZYME INHIBITORS; FLUTAMIDE; GENES, REPORTER; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LIGANDS; MALE; MODELS, BIOLOGICAL; MORPHOLINES; NUCLEAR PROTEINS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN BIOSYNTHESIS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR PROTEIN-TYROSINE KINASES; RNA; SIGNAL TRANSDUCTION; TIME FACTORS; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTORS; TRANSFECTION; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 0038004462     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (67)

1. Matsushima, H., Goto, T., Hosaka, Y., Kitamura, T., and Kawabe, K. Correlation between proliferation, apoptosis, and angiogenesis in prostate carcinoma and their relation to androgen ablation. Cancer (Phila.), 85: 1822-1827, 1999.
2. Hanahan, D., and Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 86: 353-364, 1996.
3. Zetter, B. R. Angiogenesis and tumor metastasis. Annu. Rev. Med., 49: 407-424, 1998.
4. Dvorak, H. F., Brown, L. F., Detmar, M., and Dvorak, A. M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol., 146: 1029-1039, 1995.
5. Ferrer, F. A., Miller, L. J., Andrawis, R. I., Kurtzman, S. H., Albertsen, P. C., Laudone, V. P., and Kreutzer, D. L. Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells. J. Urol., 157: 2329-2333, 1997.
6. Jackson, M. W., Bentel, J. M., and Tilley, W. D. Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. J. Urol., 157: 2323-2328, 1997.
7. Warren, R. S., Yuan, H., Matli, M. R., Ferrara, N., and Donner, D. B. Induction of vascular endothelial growth factor by insulin-like growth factor 1 in colorectal carcinoma. J. Biol. Chem., 271: 29483-29488, 1996.
8. Nakamura, J., Savinov, A., Lu, Q., and Brodie, A. Estrogen regulates vascular endothelial growth/permeability factor expression in 7, 12-dimethylbenz(a)anthracene-induced rat mammary tumors. Endocrinology, 137: 5589-5596, 1996.
9. McLaren, J., Prentice, A., Charnock-Jones, D. S., Millican, S. A., Muller, K. H., Sharkey, A. M., and Smith, S. K. Vascular endothelial growth factor is produced by peritoneal fluid macrophages in endometriosis and is regulated by ovarian steroids. J. Clin. Investig., 98: 482-489, 1996.
10. Goldberg, M. A., and Schneider, T. J. Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin. J. Biol. Chem., 269: 4355-4359, 1994.
11. Hlatky, L., Tsionou, C., Hahnfeldt, P., and Coleman, C. N. Mammary fibroblasts may influence breast tumor angiogenesis via hypoxia-induced vascular endothelial growth factor up-regulation and protein expression. Cancer Res., 54: 6083-6086, 1994.
12. Cohen, T., Nahari, D., Cerem, L. W., Neufeld, G., and Levi, B. Z. Interleukin 6 induces the expression of vascular endothelial growth factor. J. Biol. Chem., 271: 736-741, 1996.
13. Hyder, S. M., Stancel, G. M., Chiappetta, C., Murthy, L., Boettger-Tong, H. L., and Makela, S. Uterine expression of vascular endothelial growth factor is increased by estradiol and tamoxifen. Cancer Res., 56: 3954-3960, 1996.
14. Heiss, J. D., Papavassiliou, E., Merrill, M. J., Nieman, L., Knightly, J. J., Walbridge, S., Edwards, N. A., and Oldfield, E. H. Mechanism of dexamethasone suppression of brain tumor-associated vascular permeability in rats. Involvement of the glucocorticoid receptor and vascular permeability factor. J. Clin. Investig., 98: 1400-1408, 1996.
15. Minchenko, A., Bauer, T., Salceda, S., and Caro, J. Hypoxic stimulation of vascular endothelial growth factor expression in vitro and in vivo. Lab. Investig., 71: 374-379, 1994.
16. Minchenko, A., Salceda, S., Bauer, T., and Caro, J. Hypoxia regulatory elements of the human vascular endothelial growth factor gene. Cell Mol. Biol. Res., 40: 35-39, 1994.
17. Plate, K. H., Breier, G., Millauer, B., Ullrich, A., and Risau, W. Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res., 53: 5822-5827, 1993.
18. Shweiki, D., Itin, A., Soffer, D., and Keshet, E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature (Lond.), 359: 843-845, 1992.
19. Mazure, N. M., Chen, E. Y., Laderoute, K. R., and Giaccia, A. J. Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood, 90: 3322-3331, 1997.
20. Forsythe, J. A., Jiang, B. H., Iyer, N. V., Agani, F., Leung, S. W., Koos, R. D., and Semenza, G. L. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol., 16: 4604-4613, 1996.
21. Liu, Y., Cox, S. R., Morita, T., and Kourembanas, S. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5′ enhancer. Circ. Res., 77: 638-643, 1995.
22. Salceda, S., Beck, I., and Caro, J. Absolute requirement of aryl hydrocarbon receptor nuclear translocator protein for gene activation by hypoxia. Arch. Biochem. Biophys., 334: 389-394, 1996.
23. Joseph, I. B., Nelson, J. B., Denmeade, S. R., and Isaacs, J. T. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clin. Cancer Res., 3: 2507-2511, 1997.
24. Sordello, S., Bertrand, N., and Plouet, J. Vascular endothelial growth factor is up-regulated in vitro and in vivo by androgens. Biochem. Biophys. Res. Commun., 251: 287-290, 1998.
25. Stewart, R. J., Panigrahy, D., Flynn, E., and Folkman, J. Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts. J. Urol., 165: 688-693, 2001.
26. Levine, A. C., Liu, X. H., Greenberg, P. D., Eliashvili, M., Schiff, J. D., Aaronson, S. A., Holland, J. F., and Kirschenbaum, A. Androgens induce the expression of vascular endothelial growth factor in human fetal prostatic fibroblasts. Endocrinology, 139: 4672-4678, 1998.
27. Semenza, G. L. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol. Med., 8: S62-67, 2002.
28. Epstein, A. C., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., Tian, Y. M., Masson, N., Hamilton, D. L., Jaakkola, P., Barstead, R., Hodgkin, J., Maxwell, P. H., Pugh, C. W., Schofield, C. J., and Ratcliffe, P. J. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell, 107: 43-54, 2001.
29. Zhong, H., Chiles, K., Feldser, D., Laughner, E., Hanrahan, C., Georgescu, M. M., Simons, J. W., and Semenza, G. L. Modulation of hypoxia-inducible factor 1α expression by the epidermal growth factor/ phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res., 60: 1541-1545, 2000.
30. Jiang, B. H., Jiang, G., Zheng, J. Z., Lu, Z., Hunter, T., and Vogt, P. K. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ., 12: 363-369, 2001.
31. Laughner, E., Taghavi, P., Chiles, K., Mahon, P. C., and Semenza, G. L. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1α (HIF-1α) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol. Cell. Biol., 21: 3995-4004, 2001.
32. Blancher, C., Moore, J. W., Robertson, N., and Harris, A. L. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1α. HIF-2α, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3′-kinase/Akt signaling pathway. Cancer Res., 61: 7349-7355, 2001.
33. Stiehl, D. P., Jelkmann, W., Wenger, R. H., and Hellwig-Burgel, T. Normoxic induction of the hypoxia-inducible factor 1α by insulin and interleukin-1β involves the phosphatidylinositol 3-kinase pathway. FEBS Lett., 512: 157-162, 2002.
34. Arsham, A. M., Plas, D. R., Thompson, C. B., and Simon, M. C. Phosphatidylinositol 3-kinase/Akt signaling is neither required for hypoxic stabilization of HIF-1α nor sufficient for HIF-1-dependent target gene transcription. J. Biol. Chem., 277: 15162-15170, 2002.
35. Zhong, H., De Marzo, A. M., Laughner, E., Lim, M., Hilton, D. A., Zagzag, D., Buechler, P., Isaacs, W. B., Semenza, G. L., and Simons, J. W. Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res., 59: 5830-5835, 1999.
36. Talks, K. L., Turley, H., Gatter, K. C., Maxwell, P. H., Pugh, C. W., Ratcliffe, P. J., and Harris, A. L. The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages. Am. J. Pathol., 157: 411-421, 2000.
37. Salnikow, K., Costa, M., Figg, W. D., and Blagosklonny, M. V. Hyperinducibility of hypoxia-responsive genes without p53/p21-dependent checkpoint in aggressive prostate cancer. Cancer Res., 60: 5630-5634, 2000.
38. Bos, R., Zhong, H., Hanrahan, C. F., Mommers, E. C., Semenza, G. L., Pinedo, H. M., Abeloff, M. D., Simons, J. W., van Diest, P. J., and van der Wall, E. Levels of hypoxia-inducible factor-1α during breast carcinogenesis. J. Nati. Cancer Inst., 93: 309-314, 2001.
39. Birner, P., Gatterbauer, B., Oberhuber, G., Schindl, M., Rossler, K., Prodinger, A., Budka, H., and Hainfellner, J. A. Expression of hypoxia-inducible factor-1α in oligodendrogliomas: its impact on prognosis and on neoangiogenesis. Cancer (Phila.), 92: 165-171, 2001.
40. Birner, P., Schindl, M., Obermair, A., Breitenecker, G., and Oberhuber, G. Expression of hypoxia-inducible factor 1α in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin. Cancer Res., 7: 1661-1668, 2001.
41. Birner, P., Schindl, M., Obermair, A., Plank, C., Breitenecker, G., and Oberhuber, G. Overexpression of hypoxia-inducible factor la is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res., 60: 4693-4696, 2000.
42. Koukourakis, M. I., Giatromanolaki, A., Skarlatos, J., Corti, L., Blandamura, S., Piazza, M., Gatter, K. C., and Harris, A. L. Hypoxia inducible factor (HIF-1a and HIF-2a) expression in early esophageal cancer and response to photodynamic therapy and radiotherapy. Cancer Res., 61: 1830-1832, 2001.
43. Giatromanolaki, A., Koukourakis, M. I., Sivridis, E., Pastorek, J., Wykoff, C. C., Gatter, K. C., and Harris, A. L. Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res., 61: 7992-7998, 2001.
44. Giatromanolaki, A., Koukourakis, M. I., Sivridis, E., Turley, H., Talks, K., Pezzella, F., Gatter, K. C., and Harris, A. L. Relation of hypoxia inducible factor 1 α and 2 α in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br. J. Cancer, 85: 881-890, 2001.
45. Aebersold, D. M., Burri, P., Beer, K. T., Laissue, J., Djonov, V., Greiner, R. H., and Semenza, G. L. Expression of hypoxia-inducible factor-1α: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res., 61: 2911-2916, 2001.
46. Movsas, B., Chapman, J. D., Horwitz, E. M., Pinover, W. H., Greenberg, R. E., Hanlon, A. L., Iyer, R., and Hanks, G. E. Hypoxic regions exist in human prostate carcinoma. Urology, 53: 11-18, 1999.
47. Harris, A. L. Hypoxia-a key regulatory factor in tumour growth. Nat. Rev. Cancer, 2: 38-47, 2002.
48. Jiang, B. H., Semenza, G. L., Bauer, C., and Marti, H. H. Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension. Am. J. Physiol., 271: C1172-1180, 1996.
49. Post, D. E., and Van Meir, E. G. Generation of bidirectional hypoxia/HIF-responsive expression vectors to target gene expression to hypoxic cells. Gene Ther., 8: 1801-1807, 2001.
50. Mabjeesh, N. J., Post, D. E., Willard, M. T., Kaur, B., Van Meir, E. G., Simons, J. W., and Zhong, H. Geldanamycin induces degradation of hypoxia-inducible factor 1α protein via the proteosome pathway in prostate cancer cells. Cancer Res., 62: 2478-2482, 2002.
51. Zhong, H., Agani, F., Baccala, A. A., Laughner, E., Rioseco-Camacho, N., Isaacs, W. B., Simons, J. W., and Semenza, G. L. Increased expression of hypoxia inducible factor-1α in rat and human prostate cancer. Cancer Res., 58: 5280-5284, 1998.
52. Lu, S., Gu, X., Hoestje, S., and Epner, D. E. Identification of an additional hypoxia responsive element in the glyceraldehyde-3-phosphate dehydrogenase gene promoter. Biochim. Biophys. Acta, 1574: 152-156, 2002.
53. Graven, K. K., Yu, Q., Pan, D., Roncarati, J. S., and Farber, H. W. Identification of an oxygen responsive enhancer element in the glyceraldehyde-3-phosphate dehydrogenase gene. Biochim. Biophys. Acta, 1447: 208-218, 1999.
54. Zhong, H., and Simons, J. W. Direct comparison of GAPDH, β-actin, cyclophilin, and 28S rRNA as internal standards for quantifying RNA levels under hypoxia. Biochem. Biophys. Res. Commun., 259: 523-526, 1999.
55. Semenza, G. L., Roth, P. H., Fang, H. M., and Wang, G. L. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J. Biol. Chem., 269: 23757-23763, 1994.
56. Ravenna, L., Lubrano, C., Di Silverio, F., Vacca, A., Felli, M. P., Maroder, M., D'Eramo, G., Sciarra, F., Frati, L., Gulino, A., and et al. Androgenic and antiandrogenic control on epidermal growth factor, epidermal growth factor receptor, and androgen receptor expression in human prostate cancer cell line LNCaP. Prostate, 26: 290-298, 1995.
57. Brass, A. L., Barnard, J., Patai, B. L., Salvi, D., and Rukstalis, D. B. Androgen up-regulates epidermal growth factor receptor expression and binding affinity in PC3 cell lines expressing the human androgen receptor. Cancer Res., 55: 3197-3203, 1995.
58. Vlietstra, R. J., van Alewijk, D. C., Hermans, K. G., van Steenbrugge, G. J., and Trapman, J. Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res., 58: 2720-2723, 1998.
59. Veldscholte, J., Ris-Stalpers, C., Kuiper, G. G., Jenster, G., Berrevoets, C., Claassen, E., van Rooij, H. C., Trapman, J., Brinkmann, A. O., and Mulder, E. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem. Biophys. Res. Commun., 173: 534-540, 1990.
60. Montgomery, B. T., Young, C. Y., Bilhartz, D. L., Andrews, P. E., Prescott, J. L., Thompson, N. F., and Tindall, D. J. Hormonal regulation of prostate-specific antigen (PSA) glycoprotein in the human prostatic adenocarcinoma cell line. LNCaP. Prostate, 21: 63-73, 1992.
61. Ravindranath, N., Wion, D., Brachet, P., and Djakiew, D. Epidermal growth factor modulates the expression of vascular endothelial growth factor in the human prostate. J. Androl., 22: 432-443, 2001.
62. Culig, Z., Hobisch, A., Bartsch, G., and Klocker, H. Expression and function of androgen receptor in carcinoma of the prostate. Microsc. Res. Tech., 51: 447-455, 2000.
63. Culig, Z., Hobisch, A., Bartsch, G., and Klocker, H. Androgen receptor-an update of mechanisms of action in prostate cancer. Urol. Res., 28: 211-219, 2000.
64. Semenza, G. L. Involvement of hypoxia-inducible factor 1 in human cancer. Intern. Med., 41: 79-83, 2002.
65. Mendelsohn, J. Targeting the epidermal growth factor receptor for cancer therapy. J. Clin. Oncol., 20: 1S-13S, 2002.
66. Karashima, T., Sweeney, P., Slaton, J. W., Kim, S. J., Kedar, D., Izawa, J. I., Fan, Z., Pettaway, C., Hicklin, D. J., Shuin, T., and Dinney, C. P. Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice. Clin. Cancer Res., 8: 1253-1264, 2002.
67. Ciardiello, F., Caputo, R, Bianco, R., Damiano, V., Fontanini, G., Cuccato, S., De Placido, S., Bianco, A. R., and Tortora, G. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin. Cancer Res., 7: 1459-1465, 2001.